Physician profile
Ami Amin
NPI 1144674219
$2,410.13
in general payments reported to CMS, 2019-2025
30 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.45 · 2021: $113 · 2022: $887 · 2023: $1,024 · 2024: $160 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.08 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $712.36 | 2020-2024 | Rybelsus, Ozempic, Sogroya |
| Lilly USA, LLC | $199.57 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $119.71 | 2022-2023 | |
| Amgen INC. | $110.21 | 2021-2023 | Evenity, Prolia |
| Astellas Pharma US INC | $99.99 | 2023 | Veozah |
| Dexcom, INC. | $87.46 | 2022-2023 | Dexcom G6 Transmitter |
| Cequr Corporation | $79.76 | 2022-2023 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $77.00 | 2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $74.27 | 2022-2023 | Somatuline Depot |
| Ibsa Pharma INC. | $69.82 | 2022-2023 | Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $69.07 | 2023 | |
| Xeris Pharmaceuticals, INC. | $59.94 | 2022-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $58.13 | 2022-2023 | |
| Tolmar, INC. | $57.58 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.48 | 2022-2023 | Jardiance, Tradjenta, Synjardy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $50.94 | 2024-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $48.79 | 2021-2022 | |
| Amphastar Pharmaceuticals, INC. | $48.17 | 2023-2024 | Baqsimi |
| Corcept Therapeutics | $43.01 | 2022-2024 | Korlym |
| Medtronic, INC. | $42.47 | 2022-2024 | Minimed 780g |
| Insulet Corporation | $42.37 | 2023-2025 | Omnipod |
| Abbvie INC. | $33.51 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $28.97 | 2022-2024 | Imcivree |
| Opko Pharmaceuticals, LLC | $27.73 | 2023 | Rayaldee |
| Radius Health, INC. | $27.71 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.31 | 2022 | |
| Antares Pharma, INC. | $22.14 | 2025 | Xyosted |
| Madrigal Pharmaceuticals | $14.46 | 2025 | Rezdiffra |
| Intuity Medical INC | $14.38 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amryt Pharma Holdings Ltd | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.